Case Studies: Drug Withdrawals Based on Phase 4 Clinical Trial Data

Published on 21/12/2025

How Phase 4 Clinical Trials Have Led to Drug Withdrawals: Key Case Studies and Lessons Learned

Table of Contents

Introduction

While Phase 1–3 clinical trials are essential for regulatory approval, they often take place in controlled environments with limited patient diversity and short follow-up periods. Once a drug reaches the market, Phase 4 clinical trials serve as the critical line of defense for long-term safety monitoring. In some cases, real-world evidence collected during Phase 4 has exposed serious risks that were not detected in earlier phases—ultimately leading to product withdrawal from the market.

This article presents notable case studies of drug withdrawals driven by Phase 4 findings, outlining key pharmacovigilance signals, regulatory responses, and lessons learned for future post-marketing surveillance programs.

What Triggers Drug Withdrawal in Phase 4?

Previously undetected adverse events such as cardiovascular risks, hepatotoxicity, or cancer
High incidence of serious adverse events (SAEs) in broader real-world populations
Off-label misuse leading to complications
Failure to meet real-world effectiveness expectations
Safety signals from spontaneous reports, registries, or RWE studies

Case Study 1: Rofecoxib (Vioxx)

Background

Approved in 1999 by the FDA, Rofecoxib was a COX-2 inhibitor used to treat osteoarthritis and acute pain.

Withdrawal

In 2004, Merck voluntarily withdrew Vioxx after Phase 4 studies,

particularly the APPROVe trial, showed increased risk of heart attack and stroke in patients who used the drug for over 18 months.

Lesson Learned

Phase 4 cardiovascular outcomes studies are essential for pain and inflammation drugs
Signal detection must be proactive and communicated transparently to regulators and the public

Case Study 2: Cisapride (Propulsid)

Background

Cisapride was approved to treat gastroesophageal reflux disease (GERD). It was widely prescribed off-label for infants and patients with other motility disorders.

Withdrawal

Phase 4 post-marketing surveillance revealed serious cardiac arrhythmias, including torsades de pointes and sudden death, particularly in patients with hepatic impairment or on interacting medications. It was withdrawn in 2000.

Lesson Learned

Pharmacokinetic studies in special populations (e.g., hepatic impairment) must be extended to Phase 4
Drug-drug interaction surveillance is critical post-marketing

Case Study 3: Cerivastatin (Baycol)

Background

Cerivastatin, a statin used to lower cholesterol, was launched in the late 1990s.

Withdrawal

By 2001, Bayer withdrew the drug after over 50 fatal cases of rhabdomyolysis were reported through Phase 4 data and spontaneous reporting systems, especially when used with gemfibrozil.

Lesson Learned

Post-marketing surveillance for drug combinations is critical in high-risk therapeutic areas like lipid lowering
Risk mitigation should include dosage limits and contraindications promptly updated based on Phase 4 data

Case Study 4: Tegaserod (Zelnorm)

Background

Tegaserod was approved for irritable bowel syndrome with constipation (IBS-C) in women.

Withdrawal

Phase 4 safety analysis indicated increased cardiovascular events, prompting voluntary withdrawal in 2007. It was later reapproved with restricted use in 2019 under a REMS program.

Lesson Learned

Withdrawal isn’t always final—REMS and targeted access programs can reinstate drugs under controlled conditions
Phase 4 trials can refine patient selection criteria and access strategy

Case Study 5: Alosetron (Lotronex)

Background

Alosetron was used for severe diarrhea-predominant IBS in women.

Withdrawal and Reinstatement

It was withdrawn in 2000 after severe adverse GI events (including ischemic colitis) were reported post-marketing. Reapproved in 2002 with strict risk management measures.

Lesson Learned

Phase 4 data helped develop a REMS strategy including physician enrollment and patient consent

Global Regulatory Pathways for Phase 4-Informed Withdrawal

FDA

Uses MedWatch, Sentinel, and post-marketing requirements (PMRs) to evaluate risk
Can initiate market withdrawal or mandate label changes under FDCA

EMA

Utilizes EudraVigilance, PRAC, and PASS to review and act upon safety signals
Can suspend or revoke MA under Article 107i of Directive 2001/83/EC

CDSCO

Relies on PvPI, regional hospital surveillance, and PSURs to monitor safety
Withdrawals initiated via SEC recommendation and DGCI decision

Best Practices for Sponsors

Include risk evaluation and mitigation strategies (REMS or RMPs) as part of Phase 4 planning
Implement centralized adverse event dashboards and periodic risk reviews
Share Phase 4 safety data transparently with stakeholders, including HTA bodies and the public
Prepare regulatory templates for MAH notifications and recall procedures

Conclusion

Phase 4 clinical trials are not just a formality—they are often the frontline of patient protection and public health assurance. These case studies demonstrate the power of real-world data in detecting safety issues, prompting regulatory action, and refining the use of medicines. At ClinicalStudies.in, we help sponsors implement proactive Phase 4 safety strategies to ensure product longevity, ethical responsibility, and global regulatory compliance.